Intercept’s NASH drug is rejected by FDA, company will restructure in pivot from disease

Intercept Pharmaceuticals’ NASH drug obeticholic acid was rejected by the FDA for a second time on Thursday, and the company says it will now discontinue “all NASH-related investment” and pivot its focus to rare and serious liver diseases.

A resubmission would require, at a minimum, complete data from the long-term…
Click here to view original post

Advertisement — Advertise with Biotech Networks